Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users
Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80 Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current stu...
Saved in:
| Published in | Neuropsychopharmacology (New York, N.Y.) Vol. 39; no. 13; pp. 3087 - 3099 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basingstoke
Nature Publishing Group
01.12.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0893-133X 1740-634X 1740-634X |
| DOI | 10.1038/npp.2014.166 |
Cover
Loading…
| Abstract | Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80 Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current study therefore utilized electroencephalography (EEG) to examine gamma oscillations during coherent motion perception in heavy cannabis users and controls. Chronic cannabis users (n = 24; 12 h abstinence before study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive controls (n = 23) were evaluated. Stimuli consisted of random dot kinetograms (RDKs) that subjects passively viewed during three different conditions: coherent motion, incoherent motion, and static. Time × frequency analysis on EEG data was performed using Fourier-based mean trial power (MTP). Transient event-related potentials (ERPs) to stimulus onset (visual N100 and P200 components) were also evaluated. The results showed that the coherent motion condition produced a robust increase in neural activity in the gamma range (induced power from 40 to 59 Hz) as compared with the incoherent motion and static conditions. As predicted, the cannabis group showed significant reductions in induced gamma power in the coherent condition relative to healthy controls. No differences were observed between the groups in the N100 or P200 components, indicating intact primary sensory processing. Finally, cannabis users showed a trend toward increased scores on the Chapman Perceptual Aberration Scale (PAS) that was positively correlated with total years of active cannabis use. These data suggest that cannabis use may interfere with the generation of induced gamma-band neural oscillations that could in part mediate the perceptual-altering effects of exogenous cannabinoids. |
|---|---|
| AbstractList | Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30–80 Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current study therefore utilized electroencephalography (EEG) to examine gamma oscillations during coherent motion perception in heavy cannabis users and controls. Chronic cannabis users (
n
=24; 12 h abstinence before study; positive 11-
nor
-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive controls (
n
=23) were evaluated. Stimuli consisted of random dot kinetograms (RDKs) that subjects passively viewed during three different conditions: coherent motion, incoherent motion, and static. Time × frequency analysis on EEG data was performed using Fourier-based mean trial power (MTP). Transient event-related potentials (ERPs) to stimulus onset (visual N100 and P200 components) were also evaluated. The results showed that the coherent motion condition produced a robust increase in neural activity in the gamma range (induced power from 40 to 59 Hz) as compared with the incoherent motion and static conditions. As predicted, the cannabis group showed significant reductions in induced gamma power in the coherent condition relative to healthy controls. No differences were observed between the groups in the N100 or P200 components, indicating intact primary sensory processing. Finally, cannabis users showed a trend toward increased scores on the Chapman Perceptual Aberration Scale (PAS) that was positively correlated with total years of active cannabis use. These data suggest that cannabis use may interfere with the generation of induced gamma-band neural oscillations that could in part mediate the perceptual-altering effects of exogenous cannabinoids. Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current study therefore utilized electroencephalography (EEG) to examine gamma oscillations during coherent motion perception in heavy cannabis users and controls. Chronic cannabis users (n=24; 12h abstinence before study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive controls (n=23) were evaluated. Stimuli consisted of random dot kinetograms (RDKs) that subjects passively viewed during three different conditions: coherent motion, incoherent motion, and static. Time × frequency analysis on EEG data was performed using Fourier-based mean trial power (MTP). Transient event-related potentials (ERPs) to stimulus onset (visual N100 and P200 components) were also evaluated. The results showed that the coherent motion condition produced a robust increase in neural activity in the gamma range (induced power from 40 to 59Hz) as compared with the incoherent motion and static conditions. As predicted, the cannabis group showed significant reductions in induced gamma power in the coherent condition relative to healthy controls. No differences were observed between the groups in the N100 or P200 components, indicating intact primary sensory processing. Finally, cannabis users showed a trend toward increased scores on the Chapman Perceptual Aberration Scale (PAS) that was positively correlated with total years of active cannabis use. These data suggest that cannabis use may interfere with the generation of induced gamma-band neural oscillations that could in part mediate the perceptual-altering effects of exogenous cannabinoids. Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80 Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current study therefore utilized electroencephalography (EEG) to examine gamma oscillations during coherent motion perception in heavy cannabis users and controls. Chronic cannabis users (n=24; 12 h abstinence before study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive controls (n=23) were evaluated. Stimuli consisted of random dot kinetograms (RDKs) that subjects passively viewed during three different conditions: coherent motion, incoherent motion, and static. Time frequency analysis on EEG data was performed using Fourier-based mean trial power (MTP). Transient event-related potentials (ERPs) to stimulus onset (visual N100 and P200 components) were also evaluated. The results showed that the coherent motion condition produced a robust increase in neural activity in the gamma range (induced power from 40 to 59 Hz) as compared with the incoherent motion and static conditions. As predicted, the cannabis group showed significant reductions in induced gamma power in the coherent condition relative to healthy controls. No differences were observed between the groups in the N100 or P200 components, indicating intact primary sensory processing. Finally, cannabis users showed a trend toward increased scores on the Chapman Perceptual Aberration Scale (PAS) that was positively correlated with total years of active cannabis use. These data suggest that cannabis use may interfere with the generation of induced gamma-band neural oscillations that could in part mediate the perceptual-altering effects of exogenous cannabinoids. Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80 Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current study therefore utilized electroencephalography (EEG) to examine gamma oscillations during coherent motion perception in heavy cannabis users and controls. Chronic cannabis users (n = 24; 12 h abstinence before study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive controls (n = 23) were evaluated. Stimuli consisted of random dot kinetograms (RDKs) that subjects passively viewed during three different conditions: coherent motion, incoherent motion, and static. Time × frequency analysis on EEG data was performed using Fourier-based mean trial power (MTP). Transient event-related potentials (ERPs) to stimulus onset (visual N100 and P200 components) were also evaluated. The results showed that the coherent motion condition produced a robust increase in neural activity in the gamma range (induced power from 40 to 59 Hz) as compared with the incoherent motion and static conditions. As predicted, the cannabis group showed significant reductions in induced gamma power in the coherent condition relative to healthy controls. No differences were observed between the groups in the N100 or P200 components, indicating intact primary sensory processing. Finally, cannabis users showed a trend toward increased scores on the Chapman Perceptual Aberration Scale (PAS) that was positively correlated with total years of active cannabis use. These data suggest that cannabis use may interfere with the generation of induced gamma-band neural oscillations that could in part mediate the perceptual-altering effects of exogenous cannabinoids.Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80 Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current study therefore utilized electroencephalography (EEG) to examine gamma oscillations during coherent motion perception in heavy cannabis users and controls. Chronic cannabis users (n = 24; 12 h abstinence before study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive controls (n = 23) were evaluated. Stimuli consisted of random dot kinetograms (RDKs) that subjects passively viewed during three different conditions: coherent motion, incoherent motion, and static. Time × frequency analysis on EEG data was performed using Fourier-based mean trial power (MTP). Transient event-related potentials (ERPs) to stimulus onset (visual N100 and P200 components) were also evaluated. The results showed that the coherent motion condition produced a robust increase in neural activity in the gamma range (induced power from 40 to 59 Hz) as compared with the incoherent motion and static conditions. As predicted, the cannabis group showed significant reductions in induced gamma power in the coherent condition relative to healthy controls. No differences were observed between the groups in the N100 or P200 components, indicating intact primary sensory processing. Finally, cannabis users showed a trend toward increased scores on the Chapman Perceptual Aberration Scale (PAS) that was positively correlated with total years of active cannabis use. These data suggest that cannabis use may interfere with the generation of induced gamma-band neural oscillations that could in part mediate the perceptual-altering effects of exogenous cannabinoids. Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80 Hz). However, no studies to date have examined the effect of cannabis on non-time-locked, induced gamma oscillations during more complex Gestalt perception. The current study therefore utilized electroencephalography (EEG) to examine gamma oscillations during coherent motion perception in heavy cannabis users and controls. Chronic cannabis users (n = 24; 12 h abstinence before study; positive 11-nor-9-carboxy-delta-9-tetrahydrocannabinol urine levels) and cannabis-naive controls (n = 23) were evaluated. Stimuli consisted of random dot kinetograms (RDKs) that subjects passively viewed during three different conditions: coherent motion, incoherent motion, and static. Time × frequency analysis on EEG data was performed using Fourier-based mean trial power (MTP). Transient event-related potentials (ERPs) to stimulus onset (visual N100 and P200 components) were also evaluated. The results showed that the coherent motion condition produced a robust increase in neural activity in the gamma range (induced power from 40 to 59 Hz) as compared with the incoherent motion and static conditions. As predicted, the cannabis group showed significant reductions in induced gamma power in the coherent condition relative to healthy controls. No differences were observed between the groups in the N100 or P200 components, indicating intact primary sensory processing. Finally, cannabis users showed a trend toward increased scores on the Chapman Perceptual Aberration Scale (PAS) that was positively correlated with total years of active cannabis use. These data suggest that cannabis use may interfere with the generation of induced gamma-band neural oscillations that could in part mediate the perceptual-altering effects of exogenous cannabinoids. |
| Author | Hetrick, William P Krishnan, Giri P D'Souza, Deepak C O'Donnell, Brian F Skosnik, Patrick D |
| Author_xml | – sequence: 1 givenname: Patrick D surname: Skosnik fullname: Skosnik, Patrick D – sequence: 2 givenname: Giri P surname: Krishnan fullname: Krishnan, Giri P – sequence: 3 givenname: Deepak C surname: D'Souza fullname: D'Souza, Deepak C – sequence: 4 givenname: William P surname: Hetrick fullname: Hetrick, William P – sequence: 5 givenname: Brian F surname: O'Donnell fullname: O'Donnell, Brian F |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28992417$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24990428$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks1v1DAQxS1URLeFG2cUCSFxIIu_7VyQYAstUqEcqNSb5TiT1lXWDnZSqf893u2Wj4oDJ1v2b57ezLwDtBdiAISeE7wkmOm3YRyXFBO-JFI-QguiOK4l4xd7aIF1w2rC2MU-Osj5GmMilNRP0D7lTYM51QvUHvmc5nGCrjq267WtP9jQVV9hTnaozrLzw2AnH0Oujubkw2W1ileQIEzVl7h5r75BcjBurz5UJ2BvbquVDcG2PlfnGVJ-ih73dsjwbHceovNPH7-vTurTs-PPq_entZNETHVrG2wldlQ2IBmjLYiu1b2VPfQUgyJcgVWMtZITbbnqdUewYERjIRxpO3aI3t3pjnO7hs4Vk6UJMya_tunWROvN3z_BX5nLeGM4pY3QtAi83gmk-GOGPJm1zw7KBALEOZsyYE6x4Ar_B0qpaBSVsqAvH6DXcU6hTGJLYSXKKgr14k_zv1zfb6oAr3aAzc4OfbLB-fyb001DOVGFo3ecSzHnBL1xftqusPTsB0Ow2cTGlNiYTWw2XZWiNw-K7nX_if8ERsTDpg |
| CODEN | NEROEW |
| CitedBy_id | crossref_primary_10_1002_cne_25098 crossref_primary_10_1016_j_neuropharm_2018_03_036 crossref_primary_10_1016_j_neuropharm_2017_03_033 crossref_primary_10_1111_ejn_14856 crossref_primary_10_3389_fpsyg_2021_679904 crossref_primary_10_1111_ejn_13810 crossref_primary_10_3389_fphar_2017_00399 crossref_primary_10_1111_ejn_15110 crossref_primary_10_1177_15500594221138280 crossref_primary_10_1016_j_biopsych_2018_07_024 crossref_primary_10_1097_CXA_0000000000000063 crossref_primary_10_1038_s41372_020_00911_9 crossref_primary_10_1038_srep43780 crossref_primary_10_1111_adb_12370 crossref_primary_10_1002_hbm_25634 crossref_primary_10_3390_jpm11010017 crossref_primary_10_1101_lm_046748_117 crossref_primary_10_1016_j_biopsych_2015_12_011 crossref_primary_10_1016_j_euroneuro_2017_10_038 crossref_primary_10_1111_adb_70023 |
| Cites_doi | 10.1016/j.mce.2008.02.011 10.1111/j.1556-4029.2010.01441.x 10.1016/S0306-4522(97)00436-3 10.1038/nn1801 10.1146/annurev.neuro.26.041002.131052 10.1615/CritRevNeurobiol.v15.i2.10 10.1016/S0167-8760(97)00763-0 10.1016/j.clinph.2005.09.024 10.1016/j.psychres.2010.07.035 10.1093/schbul/sbn070 10.1523/JNEUROSCI.11-09-02768.1991 10.1016/S0167-8760(00)00166-5 10.1016/j.neuroscience.2010.06.011 10.1016/j.biopsych.2007.12.005 10.1016/0013-4694(83)90135-9 10.1038/sj.npp.1301506 10.1176/appi.ajp.2012.12030373 10.1523/JNEUROSCI.4623-06.2007 10.1111/j.1460-9568.2010.07165.x 10.1001/jama.287.9.1123 10.1007/s00221-002-1252-0 10.3109/14992020309101316 10.1124/pr.110.003004 10.1152/physrev.00035.2008 10.1016/j.tins.2009.05.006 10.1016/j.euroneuro.2008.06.009 10.1016/j.neuron.2008.04.020 10.1523/JNEUROSCI.19-16-07162.1999 10.1038/373612a0 10.1016/S0896-6273(00)80326-8 10.1093/schbul/sbn093 10.1097/00001756-200504250-00022 10.1073/pnas.93.12.6112 10.1016/S0022-3565(25)32251-2 10.1176/ajp.2006.163.10.1798 10.1073/pnas.78.4.2643 10.1006/nimg.2002.1085 10.1016/j.conb.2008.08.007 10.1146/annurev-neuro-062111-150444 10.1016/j.tips.2006.12.004 10.1093/cercor/bhj136 10.1073/pnas.1934854100 10.1016/0304-3940(94)11109-V 10.1016/S0896-6273(00)80821-1 10.1523/JNEUROSCI.4587-05.2006 10.1038/mp.2011.82 10.1016/S0140-6736(07)61162-3 10.1016/j.jneumeth.2003.10.009 10.1037/0021-843X.87.4.399 10.1111/j.1399-5618.2010.00871.x 10.1016/j.toxlet.2010.06.002 10.1021/ja00730a036 10.1016/S0306-4522(96)00428-9 10.1111/adb.12116 10.1093/cercor/bhk025 10.1038/sj.npp.1301643 10.1016/j.neuroimage.2010.11.053 10.1046/j.1460-9568.2000.00217.x 10.1001/archgenpsychiatry.2011.5 10.1007/978-1-4757-1281-0_11 10.1073/pnas.87.5.1932 10.1097/00001756-200101220-00017 10.1152/jn.00603.2006 10.1037/a0016328 10.1016/j.neuron.2008.03.027 10.1038/nature02913 10.3389/neuro.07.017.2009 10.1126/science.1099745 10.1016/j.biopsych.2008.02.021 10.1038/npp.2012.65 10.7205/MILMED-D-10-00356 10.1038/npp.2013.164 10.1073/pnas.1217144110 10.1097/JCP.0b013e3182984015 10.1038/nrn2774 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1 10.1111/j.1460-9568.1990.tb00450.x 10.1038/383621a0 10.1016/S0026-895X(25)09876-1 10.1016/S0163-7258(00)00038-3 10.1097/00001756-199707280-00031 10.2741/3246 10.1016/S0149-7634(01)00027-6 10.1002/syn.20844 10.1523/JNEUROSCI.0404-10.2010 10.1073/pnas.88.20.8996 10.1016/j.biopsych.2010.09.021 10.1152/jn.91044.2008 10.1016/S0306-4522(00)00286-4 10.1016/S0091-3057(03)00140-0 10.1073/pnas.1206820109 10.2174/0929867306666220401124036 10.1523/JNEUROSCI.0442-05.2005 10.1038/npp.2009.71 10.1155/2008/808564 10.1177/1073858403259137 10.1001/archpsyc.56.11.1001 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS Copyright Nature Publishing Group Dec 2014 Copyright © 2014 American College of Neuropsychopharmacology 2014 American College of Neuropsychopharmacology |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: Copyright Nature Publishing Group Dec 2014 – notice: Copyright © 2014 American College of Neuropsychopharmacology 2014 American College of Neuropsychopharmacology |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 88G 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2M M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1038/npp.2014.166 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Biological Science Collection ProQuest Central (New) (NC LIVE) ProQuest Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database ProQuest Psychology Database (NC LIVE) ProQuest Biological Science Database (NC LIVE) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology Neurosciences Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Cannabinoids and gamma oscillations |
| EISSN | 1740-634X |
| EndPage | 3099 |
| ExternalDocumentID | PMC4229582 3490015221 24990428 28992417 10_1038_npp_2014_166 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: NIDA NIH HHS grantid: 1 R03 DA019630-01A1 – fundername: NIDA NIH HHS grantid: R03 DA019630 |
| GroupedDBID | --- -DZ -Q- 0R~ 29N 2WC 36B 39C 4.4 406 5RE 70F 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AANZL AASML AAYXX AAYZH ABAKF ABBRH ABDBE ABFSG ABIVO ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMFV ACMJI ACPRK ACRQY ACSTC ACZOJ ADBBV ADFRT AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG ATHPR AVWKF AYFIA AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION CS3 DIK DNIVK DPUIP DWQXO E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN F5P FDB FDQFY FERAY FIZPM FSGXE FYUFA GNUQQ GX1 HCIFZ HMCUK HYE HZ~ IWAJR JSO JZLTJ KQ8 M1P M2M M7P MK0 NQJWS O9- OK1 P2P P6G PHGZM PHGZT PQQKQ PROAC PSQYO PSYQQ Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D ZGI --K 1B1 53G 5VS AACDK AAEDT AALRI AAQFI AAQXK AATNV AAXUO ABMAC ABWVN ACIUM ACRPL ADMUD ADNMO CAG COF FEDTE FGOYB FIGPU HVGLF IHE IQODW LGEZI LOTEE M41 NADUK NQ- NXXTH R2- RIG RNS RPZ SEW SSZ ZKB ABRTQ ACVFH ADCNI AEUPX AFPUW AGQPQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 3V. 7TK 7XB 8FE 8FH 8FK K9. LK8 PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c615t-ba90a60c269e6332be5db8fa6fef20e7147ea733b6418a47f8d105318055c1bd3 |
| IEDL.DBID | 7X7 |
| ISSN | 0893-133X 1740-634X |
| IngestDate | Thu Aug 21 18:20:49 EDT 2025 Fri Jul 11 05:13:44 EDT 2025 Mon Jul 21 10:43:30 EDT 2025 Fri Jul 25 09:12:49 EDT 2025 Mon Jul 21 05:29:02 EDT 2025 Wed Apr 02 07:14:02 EDT 2025 Thu Apr 24 22:58:03 EDT 2025 Tue Jul 01 04:59:03 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | Cannabis Stimulus movement Dicotyledones Angiospermae Oscillation Cannabidaceae Spermatophyta Drug of abuse Recreational drug |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c615t-ba90a60c269e6332be5db8fa6fef20e7147ea733b6418a47f8d105318055c1bd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.nature.com/articles/npp2014166.pdf |
| PMID | 24990428 |
| PQID | 1622075904 |
| PQPubID | 33935 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4229582 proquest_miscellaneous_1664205470 proquest_miscellaneous_1622597266 proquest_journals_1622075904 pubmed_primary_24990428 pascalfrancis_primary_28992417 crossref_citationtrail_10_1038_npp_2014_166 crossref_primary_10_1038_npp_2014_166 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-12-01 |
| PublicationDateYYYYMMDD | 2014-12-01 |
| PublicationDate_xml | – month: 12 year: 2014 text: 2014-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basingstoke |
| PublicationPlace_xml | – name: Basingstoke – name: England – name: New York |
| PublicationTitle | Neuropsychopharmacology (New York, N.Y.) |
| PublicationTitleAlternate | Neuropsychopharmacology |
| PublicationYear | 2014 |
| Publisher | Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group |
| References | K Tsou (BFnpp2014166_CR95) 1998; 83 N Solowij (BFnpp2014166_CR89) 2002; 287 JB Swettenham (BFnpp2014166_CR91) 2009; 102 A Bacci (BFnpp2014166_CR3) 2004; 431 LD Johnston (BFnpp2014166_CR45) 2012 MA Whittington (BFnpp2014166_CR102) 1995; 373 C Pantev (BFnpp2014166_CR67) 1991; 88 LJ Sim-Selley (BFnpp2014166_CR82) 2003; 15 PJ Uhlhaas (BFnpp2014166_CR96) 2009; 3 RD Traub (BFnpp2014166_CR93) 2003; 100 J Hirvonen (BFnpp2014166_CR42) 2012; 17 DC D'Souza (BFnpp2014166_CR13) 2008; 33 A Delorme (BFnpp2014166_CR14) 2004; 134 M Hajos (BFnpp2014166_CR32) 2008; 63 LJ Chapman (BFnpp2014166_CR12) 1978; 87 T Harkany (BFnpp2014166_CR34) 2007; 28 Z Mehmedic (BFnpp2014166_CR58) 2010; 55 BFnpp2014166_CR5 PS Khayat (BFnpp2014166_CR48) 2010; 30 G Buzsaki (BFnpp2014166_CR10) 2012; 35 W Lutzenberger (BFnpp2014166_CR56) 1995; 183 JS Kwon (BFnpp2014166_CR53) 1999; 56 L Melloni (BFnpp2014166_CR60) 2007; 27 PD Skosnik (BFnpp2014166_CR84) 2012; 37 G Buzsaki (BFnpp2014166_CR9) 2004; 304 T Harkany (BFnpp2014166_CR35) 2008; 286 RJ Snowden (BFnpp2014166_CR88) 1991; 11 CA Hunt (BFnpp2014166_CR43) 1980; 215 MM Muller (BFnpp2014166_CR64) 1997; 8 BFnpp2014166_CR66 RG Pertwee (BFnpp2014166_CR69) 1999; 6 TH Moore (BFnpp2014166_CR61) 2007; 370 W Kruse (BFnpp2014166_CR51) 1996; 93 L Muckli (BFnpp2014166_CR63) 2002; 16 PJ Uhlhaas (BFnpp2014166_CR97) 2010; 11 C Foldy (BFnpp2014166_CR22) 2006; 26 BFnpp2014166_CR72 C Sales-Carbonell (BFnpp2014166_CR77) 2013; 110 DM Semple (BFnpp2014166_CR80) 2003; 75 I Katona (BFnpp2014166_CR47) 2000; 100 TW Picton (BFnpp2014166_CR71) 2003; 42 BFnpp2014166_CR78 RG Pertwee (BFnpp2014166_CR70) 2010; 62 M Egertova (BFnpp2014166_CR17) 2000; 422 MA Whittington (BFnpp2014166_CR101) 2000; 86 NH Morgan (BFnpp2014166_CR62) 2008; 2008 MH Meier (BFnpp2014166_CR59) 2012; 109 S Yuval-Greenberg (BFnpp2014166_CR103) 2008; 58 S Martinez-Conde (BFnpp2014166_CR57) 2009; 32 AL Bodor (BFnpp2014166_CR6) 2005; 25 KM Spencer (BFnpp2014166_CR90) 2008; 64 M Large (BFnpp2014166_CR54) 2011; 68 PD Skosnik (BFnpp2014166_CR86) 2006; 163 M Ellgren (BFnpp2014166_CR20) 2008; 18 CS Herrmann (BFnpp2014166_CR40) 2001; 25 HD Kleber (BFnpp2014166_CR49) 2012; 169 Jenny Ceccarini (BFnpp2014166_CR11) 2013; 20 G Gonzalez-Burgos (BFnpp2014166_CR29) 2008; 34 DJ Heeger (BFnpp2014166_CR37) 1999; 19 T Schanze (BFnpp2014166_CR79) 1997; 26 XJ Wang (BFnpp2014166_CR100) 2010; 90 R Galambos (BFnpp2014166_CR26) 1981; 78 D Robbe (BFnpp2014166_CR76) 2006; 9 N Naue (BFnpp2014166_CR65) 2011; 55 O Rass (BFnpp2014166_CR73) 2010; 12 Y Gaoni (BFnpp2014166_CR27) 1971; 93 RD Traub (BFnpp2014166_CR94) 1996; 383 DJ Fridberg (BFnpp2014166_CR23) 2011; 186 AB Ali (BFnpp2014166_CR1) 2010; 31 RT Born (BFnpp2014166_CR7) 2005; 28 M Glass (BFnpp2014166_CR28) 1997; 77 BJ Roach (BFnpp2014166_CR75) 2008; 34 M Herkenham (BFnpp2014166_CR39) 1990; 87 SM Eggan (BFnpp2014166_CR18) 2007; 17 J Kaiser (BFnpp2014166_CR46) 2003; 9 C Tallon-Baudry (BFnpp2014166_CR92) 2009; 14 PD Skosnik (BFnpp2014166_CR87) 2006; 117 W Singer (BFnpp2014166_CR83) 1999; 24 G Gratton (BFnpp2014166_CR30) 1983; 55 WA Devane (BFnpp2014166_CR15) 1988; 34 CM Gray (BFnpp2014166_CR31) 1990; 2 LA Johnson (BFnpp2014166_CR44) 2011; 176 PB Fitzgerald (BFnpp2014166_CR21) 2009; 34 R Galambos (BFnpp2014166_CR25) 1992 SJ Luck (BFnpp2014166_CR55) 2011; 70 O Bertrand (BFnpp2014166_CR4) 2000; 38 RG Pertwee (BFnpp2014166_CR68) 1997; 74 M Brecht (BFnpp2014166_CR8) 2001; 12 SM Raver (BFnpp2014166_CR74) 2013; 38 SM Eggan (BFnpp2014166_CR19) 2010; 169 I Vardakou (BFnpp2014166_CR98) 2010; 197 RA Andersen (BFnpp2014166_CR2) 1997; 18 PD Skosnik (BFnpp2014166_CR85) 2008; 33 C Walter (BFnpp2014166_CR99) 2013; 33 GP Krishnan (BFnpp2014166_CR50) 2005; 16 N Hajos (BFnpp2014166_CR33) 2000; 12 W Kruse (BFnpp2014166_CR52) 2002; 147 L Heng (BFnpp2014166_CR38) 2011; 65 EL Hill (BFnpp2014166_CR41) 2007; 97 M Siegel (BFnpp2014166_CR81) 2007; 17 CR Edwards (BFnpp2014166_CR16) 2009; 123 P Fries (BFnpp2014166_CR24) 2008; 58 T Harkany (BFnpp2014166_CR36) 2008; 18 24373053 - Addict Biol. 2015 Mar;20(2):357-67 21079038 - Pharmacol Rev. 2010 Dec;62(4):588-631 20813412 - Psychiatry Res. 2011 Mar 30;186(1):46-52 6941317 - Proc Natl Acad Sci U S A. 1981 Apr;78(4):2643-7 5538858 - J Am Chem Soc. 1971 Jan 13;93(1):217-24 17012692 - Am J Psychiatry. 2006 Oct;163(10):1798-805 12202074 - Neuroimage. 2002 Aug;16(4):843-56 10677026 - Neuron. 1999 Sep;24(1):49-65, 111-25 11879109 - JAMA. 2002 Mar 6;287(9):1123-31 18394789 - Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S84-90 18801434 - Curr Opin Neurobiol. 2008 Jun;18(3):338-45 18185500 - Neuropsychopharmacology. 2008 Sep;33(10):2505-16 10998107 - Eur J Neurosci. 2000 Sep;12(9):3239-49 9336020 - Pharmacol Ther. 1997;74(2):129-80 9261830 - Neuroreport. 1997 Jul 28;8(11):2575-9 9208854 - Neuron. 1997 Jun;18(6):865-72 19515947 - J Neurophysiol. 2009 Aug;102(2):1241-53 8857537 - Nature. 1996 Oct 17;383(6601):621-4 16648451 - Cereb Cortex. 2007 Mar;17(3):732-41 18586694 - Schizophr Bull. 2008 Sep;34(5):944-61 9203002 - Int J Psychophysiol. 1997 Jun;26(1-3):171-89 20542094 - Neuroscience. 2010 Sep 15;169(4):1651-61 17360907 - J Neurosci. 2007 Mar 14;27(11):2858-65 19571796 - Neuropsychopharmacology. 2009 Oct;34(11):2368-75 18261715 - Biol Psychiatry. 2008 Jun 1;63(11):1075-83 11201089 - Neuroreport. 2001 Jan 22;12(1):43-7 12428144 - Exp Brain Res. 2002 Dec;147(3):360-73 18684772 - Schizophr Bull. 2008 Sep;34(5):907-26 16022593 - Annu Rev Neurosci. 2005;28:157-89 23269835 - Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):719-24 20664082 - Physiol Rev. 2010 Jul;90(3):1195-268 20487147 - J Forensic Sci. 2010 Sep;55(5):1209-17 14678580 - Neuroscientist. 2003 Dec;9(6):475-84 15812321 - Neuroreport. 2005 Apr 25;16(6):625-30 22927402 - Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64 17115043 - Nat Neurosci. 2006 Dec;9(12):1526-33 15102499 - J Neurosci Methods. 2004 Mar 15;134(1):9-21 12106295 - Eur J Neurosci. 1990;2(7):607-619 16364685 - Clin Neurophysiol. 2006 Jan;117(1):144-56 7746482 - Neurosci Lett. 1995 Jan 2;183(1-2):39-42 19668703 - Front Integr Neurosci. 2009 Jul 30;3:17 10436069 - J Neurosci. 1999 Aug 15;19(16):7162-74 16452670 - J Neurosci. 2006 Feb 1;26(5):1465-9 21300939 - Arch Gen Psychiatry. 2011 Jun;68(6):555-61 15218136 - Science. 2004 Jun 25;304(5679):1926-9 20687106 - Synapse. 2011 Apr;65(4):278-86 23899642 - J Clin Psychopharmacol. 2013 Oct;33(5):699-705 22684592 - Am J Psychiatry. 2012 Jun;169(6):564-8 1924362 - Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8996-9000 20566335 - Toxicol Lett. 2010 Sep 1;197(3):157-62 10842224 - J Comp Neurol. 2000 Jun 26;422(2):159-71 21747398 - Mol Psychiatry. 2012 Jun;17(6):642-9 18466752 - Neuron. 2008 May 8;58(3):429-41 10799713 - Pharmacol Ther. 2000 May;86(2):171-90 19273069 - Front Biosci (Landmark Ed). 2009;14:321-32 11102663 - Int J Psychophysiol. 2000 Dec 1;38(3):211-23 12957220 - Pharmacol Biochem Behav. 2003 Jul;75(4):789-93 19634950 - Behav Neurosci. 2009 Aug;123(4):894-904 20087360 - Nat Rev Neurosci. 2010 Feb;11(2):100-13 2308954 - Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6 6256518 - J Pharmacol Exp Ther. 1980 Oct;215(1):35-44 20484646 - J Neurosci. 2010 May 19;30(20):7037-48 12790346 - Int J Audiol. 2003 Jun;42(4):177-219 9460749 - Neuroscience. 1998 Mar;83(2):393-411 17637608 - Neuropsychopharmacology. 2008 May;33(6):1432-40 11036213 - Neuroscience. 2000;100(4):797-804 16033894 - J Neurosci. 2005 Jul 20;25(29):6845-56 7854418 - Nature. 1995 Feb 16;373(6515):612-5 11595268 - Neurosci Biobehav Rev. 2001 Aug;25(6):465-76 22443509 - Annu Rev Neurosci. 2012;35:203-25 17222464 - Trends Pharmacol Sci. 2007 Feb;28(2):83-92 681612 - J Abnorm Psychol. 1978 Aug;87(4):399-407 10565499 - Arch Gen Psychiatry. 1999 Nov;56(11):1001-5 18466741 - Neuron. 2008 May 8;58(3):303-5 2848184 - Mol Pharmacol. 1988 Nov;34(5):605-13 16467563 - Cereb Cortex. 2007 Jan;17(1):175-91 15372034 - Nature. 2004 Sep 16;431(7006):312-6 8650228 - Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6112-7 21702397 - Mil Med. 2011 Jun;176(6):718-20 22713908 - Neuropsychopharmacology. 2012 Sep;37(10):2184-93 19716186 - Trends Neurosci. 2009 Sep;32(9):463-75 19079598 - Neural Plast. 2008;2008:808564 21111401 - Biol Psychiatry. 2011 Jul 1;70(1):28-34 1880548 - J Neurosci. 1991 Sep;11(9):2768-85 20345910 - Eur J Neurosci. 2010 Apr;31(7):1196-207 10469884 - Curr Med Chem. 1999 Aug;6(8):635-64 23822952 - Neuropsychopharmacology. 2013 Nov;38(12):2338-47 21176026 - Bipolar Disord. 2010 Dec;12(8):793-803 6187540 - Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):468-84 17662880 - Lancet. 2007 Jul 28;370(9584):319-28 17267760 - J Neurophysiol. 2007 Apr;97(4):2580-9 9472392 - Neuroscience. 1997 Mar;77(2):299-318 12960382 - Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11047-52 18400208 - Biol Psychiatry. 2008 Sep 1;64(5):369-75 18674887 - Eur Neuropsychopharmacol. 2008 Nov;18(11):826-34 14977366 - Crit Rev Neurobiol. 2003;15(2):91-119 21130171 - Neuroimage. 2011 Mar 15;55(2):808-17 |
| References_xml | – volume: 286 start-page: S84 issue: 1-2 Suppl 1 year: 2008 ident: BFnpp2014166_CR35 publication-title: Mol Cell Endocrinol doi: 10.1016/j.mce.2008.02.011 – volume: 55 start-page: 1209 year: 2010 ident: BFnpp2014166_CR58 publication-title: J Forensic Sci doi: 10.1111/j.1556-4029.2010.01441.x – volume: 83 start-page: 393 year: 1998 ident: BFnpp2014166_CR95 publication-title: Neuroscience doi: 10.1016/S0306-4522(97)00436-3 – volume: 9 start-page: 1526 year: 2006 ident: BFnpp2014166_CR76 publication-title: Nat Neurosci doi: 10.1038/nn1801 – volume: 28 start-page: 157 year: 2005 ident: BFnpp2014166_CR7 publication-title: Annu Rev Neurosci doi: 10.1146/annurev.neuro.26.041002.131052 – volume: 15 start-page: 91 year: 2003 ident: BFnpp2014166_CR82 publication-title: Crit Rev Neurobiol doi: 10.1615/CritRevNeurobiol.v15.i2.10 – volume: 26 start-page: 171 year: 1997 ident: BFnpp2014166_CR79 publication-title: Int J Psychophysiol doi: 10.1016/S0167-8760(97)00763-0 – volume: 117 start-page: 144 year: 2006 ident: BFnpp2014166_CR87 publication-title: Clin Neurophysiol doi: 10.1016/j.clinph.2005.09.024 – volume: 186 start-page: 46 year: 2011 ident: BFnpp2014166_CR23 publication-title: Psychiatry Res doi: 10.1016/j.psychres.2010.07.035 – volume: 34 start-page: 944 year: 2008 ident: BFnpp2014166_CR29 publication-title: Schizophr Bull doi: 10.1093/schbul/sbn070 – volume: 11 start-page: 2768 year: 1991 ident: BFnpp2014166_CR88 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.11-09-02768.1991 – volume: 38 start-page: 211 year: 2000 ident: BFnpp2014166_CR4 publication-title: Int J Psychophysiol doi: 10.1016/S0167-8760(00)00166-5 – volume: 169 start-page: 1651 year: 2010 ident: BFnpp2014166_CR19 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2010.06.011 – volume: 63 start-page: 1075 year: 2008 ident: BFnpp2014166_CR32 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2007.12.005 – volume: 55 start-page: 468 year: 1983 ident: BFnpp2014166_CR30 publication-title: Electroencephalogr Clin Neurophysiol doi: 10.1016/0013-4694(83)90135-9 – volume: 33 start-page: 1432 year: 2008 ident: BFnpp2014166_CR85 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1301506 – volume: 169 start-page: 564 year: 2012 ident: BFnpp2014166_CR49 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2012.12030373 – volume: 27 start-page: 2858 year: 2007 ident: BFnpp2014166_CR60 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.4623-06.2007 – volume: 31 start-page: 1196 year: 2010 ident: BFnpp2014166_CR1 publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.2010.07165.x – volume: 287 start-page: 1123 year: 2002 ident: BFnpp2014166_CR89 publication-title: JAMA doi: 10.1001/jama.287.9.1123 – volume: 147 start-page: 360 year: 2002 ident: BFnpp2014166_CR52 publication-title: Exp Brain Res doi: 10.1007/s00221-002-1252-0 – volume: 42 start-page: 177 year: 2003 ident: BFnpp2014166_CR71 publication-title: Int J Audiol doi: 10.3109/14992020309101316 – volume: 74 start-page: 129 year: 1997 ident: BFnpp2014166_CR68 publication-title: Pharmacol Ther – volume: 62 start-page: 588 year: 2010 ident: BFnpp2014166_CR70 publication-title: Pharmacol Rev doi: 10.1124/pr.110.003004 – volume: 90 start-page: 1195 year: 2010 ident: BFnpp2014166_CR100 publication-title: Physiol Rev doi: 10.1152/physrev.00035.2008 – volume: 32 start-page: 463 year: 2009 ident: BFnpp2014166_CR57 publication-title: Trends Neurosci doi: 10.1016/j.tins.2009.05.006 – volume: 18 start-page: 826 year: 2008 ident: BFnpp2014166_CR20 publication-title: Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2008.06.009 – ident: BFnpp2014166_CR78 – volume: 58 start-page: 303 year: 2008 ident: BFnpp2014166_CR24 publication-title: Neuron doi: 10.1016/j.neuron.2008.04.020 – volume: 19 start-page: 7162 year: 1999 ident: BFnpp2014166_CR37 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.19-16-07162.1999 – volume: 373 start-page: 612 year: 1995 ident: BFnpp2014166_CR102 publication-title: Nature doi: 10.1038/373612a0 – volume: 18 start-page: 865 year: 1997 ident: BFnpp2014166_CR2 publication-title: Neuron doi: 10.1016/S0896-6273(00)80326-8 – volume: 34 start-page: 907 year: 2008 ident: BFnpp2014166_CR75 publication-title: Schizophr Bull doi: 10.1093/schbul/sbn093 – volume-title: Monitoring the Future national results on adolescent drug use: Overview of key findings, 2011 year: 2012 ident: BFnpp2014166_CR45 – volume: 16 start-page: 625 year: 2005 ident: BFnpp2014166_CR50 publication-title: Neuroreport doi: 10.1097/00001756-200504250-00022 – volume: 93 start-page: 6112 year: 1996 ident: BFnpp2014166_CR51 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.12.6112 – volume: 215 start-page: 35 year: 1980 ident: BFnpp2014166_CR43 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)32251-2 – volume: 163 start-page: 1798 year: 2006 ident: BFnpp2014166_CR86 publication-title: Am J Psychiatry doi: 10.1176/ajp.2006.163.10.1798 – volume: 78 start-page: 2643 year: 1981 ident: BFnpp2014166_CR26 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.78.4.2643 – volume: 16 start-page: 843 year: 2002 ident: BFnpp2014166_CR63 publication-title: Neuroimage doi: 10.1006/nimg.2002.1085 – volume: 18 start-page: 338 year: 2008 ident: BFnpp2014166_CR36 publication-title: Curr Opin Neurobiol doi: 10.1016/j.conb.2008.08.007 – volume: 35 start-page: 203 year: 2012 ident: BFnpp2014166_CR10 publication-title: Annu Rev Neurosci doi: 10.1146/annurev-neuro-062111-150444 – volume: 28 start-page: 83 year: 2007 ident: BFnpp2014166_CR34 publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2006.12.004 – volume: 17 start-page: 175 year: 2007 ident: BFnpp2014166_CR18 publication-title: Cereb Cortex doi: 10.1093/cercor/bhj136 – volume: 100 start-page: 11047 year: 2003 ident: BFnpp2014166_CR93 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1934854100 – volume: 183 start-page: 39 year: 1995 ident: BFnpp2014166_CR56 publication-title: Neurosci Lett doi: 10.1016/0304-3940(94)11109-V – ident: BFnpp2014166_CR66 – volume: 24 start-page: 49 year: 1999 ident: BFnpp2014166_CR83 publication-title: Neuron doi: 10.1016/S0896-6273(00)80821-1 – volume: 26 start-page: 1465 year: 2006 ident: BFnpp2014166_CR22 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.4587-05.2006 – volume: 17 start-page: 642 year: 2012 ident: BFnpp2014166_CR42 publication-title: Mol Psychiatry doi: 10.1038/mp.2011.82 – volume: 370 start-page: 319 year: 2007 ident: BFnpp2014166_CR61 publication-title: Lancet doi: 10.1016/S0140-6736(07)61162-3 – volume: 134 start-page: 9 year: 2004 ident: BFnpp2014166_CR14 publication-title: J Neurosci Methods doi: 10.1016/j.jneumeth.2003.10.009 – volume: 87 start-page: 399 year: 1978 ident: BFnpp2014166_CR12 publication-title: J Abnorm Psychol doi: 10.1037/0021-843X.87.4.399 – volume: 12 start-page: 793 year: 2010 ident: BFnpp2014166_CR73 publication-title: Bipolar Disord doi: 10.1111/j.1399-5618.2010.00871.x – volume: 197 start-page: 157 year: 2010 ident: BFnpp2014166_CR98 publication-title: Toxicol Lett doi: 10.1016/j.toxlet.2010.06.002 – volume: 93 start-page: 217 year: 1971 ident: BFnpp2014166_CR27 publication-title: J Am Chem Soc doi: 10.1021/ja00730a036 – volume: 77 start-page: 299 year: 1997 ident: BFnpp2014166_CR28 publication-title: Neuroscience doi: 10.1016/S0306-4522(96)00428-9 – ident: BFnpp2014166_CR72 – volume: 20 start-page: 357 issue: 2 year: 2013 ident: BFnpp2014166_CR11 publication-title: Addiction Biology doi: 10.1111/adb.12116 – volume: 17 start-page: 732 year: 2007 ident: BFnpp2014166_CR81 publication-title: Cereb Cortex doi: 10.1093/cercor/bhk025 – volume: 33 start-page: 2505 year: 2008 ident: BFnpp2014166_CR13 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1301643 – volume: 55 start-page: 808 year: 2011 ident: BFnpp2014166_CR65 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2010.11.053 – volume: 12 start-page: 3239 year: 2000 ident: BFnpp2014166_CR33 publication-title: Eur J Neurosci doi: 10.1046/j.1460-9568.2000.00217.x – volume: 68 start-page: 555 year: 2011 ident: BFnpp2014166_CR54 publication-title: Arch Gen Psychiatry doi: 10.1001/archgenpsychiatry.2011.5 – start-page: 201 volume-title: Induced Rhythms in the Brain year: 1992 ident: BFnpp2014166_CR25 doi: 10.1007/978-1-4757-1281-0_11 – volume: 87 start-page: 1932 year: 1990 ident: BFnpp2014166_CR39 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.87.5.1932 – volume: 12 start-page: 43 year: 2001 ident: BFnpp2014166_CR8 publication-title: Neuroreport doi: 10.1097/00001756-200101220-00017 – volume: 97 start-page: 2580 year: 2007 ident: BFnpp2014166_CR41 publication-title: J Neurophysiol doi: 10.1152/jn.00603.2006 – volume: 123 start-page: 894 year: 2009 ident: BFnpp2014166_CR16 publication-title: Behav Neurosci doi: 10.1037/a0016328 – volume: 58 start-page: 429 year: 2008 ident: BFnpp2014166_CR103 publication-title: Neuron doi: 10.1016/j.neuron.2008.03.027 – volume: 431 start-page: 312 year: 2004 ident: BFnpp2014166_CR3 publication-title: Nature doi: 10.1038/nature02913 – volume: 3 start-page: 17 year: 2009 ident: BFnpp2014166_CR96 publication-title: Front Integr Neurosci doi: 10.3389/neuro.07.017.2009 – volume: 304 start-page: 1926 year: 2004 ident: BFnpp2014166_CR9 publication-title: Science doi: 10.1126/science.1099745 – volume: 64 start-page: 369 year: 2008 ident: BFnpp2014166_CR90 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2008.02.021 – volume: 37 start-page: 2184 year: 2012 ident: BFnpp2014166_CR84 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2012.65 – volume: 176 start-page: 718 year: 2011 ident: BFnpp2014166_CR44 publication-title: Mil Med doi: 10.7205/MILMED-D-10-00356 – volume: 38 start-page: 2338 year: 2013 ident: BFnpp2014166_CR74 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2013.164 – volume: 110 start-page: 719 year: 2013 ident: BFnpp2014166_CR77 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1217144110 – volume: 33 start-page: 699 year: 2013 ident: BFnpp2014166_CR99 publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0b013e3182984015 – volume: 11 start-page: 100 year: 2010 ident: BFnpp2014166_CR97 publication-title: Nat Rev Neurosci doi: 10.1038/nrn2774 – volume: 422 start-page: 159 year: 2000 ident: BFnpp2014166_CR17 publication-title: J Comp Neurol doi: 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1 – volume: 2 start-page: 607 year: 1990 ident: BFnpp2014166_CR31 publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.1990.tb00450.x – volume: 383 start-page: 621 year: 1996 ident: BFnpp2014166_CR94 publication-title: Nature doi: 10.1038/383621a0 – volume: 34 start-page: 605 year: 1988 ident: BFnpp2014166_CR15 publication-title: Mol Pharmacol doi: 10.1016/S0026-895X(25)09876-1 – volume: 86 start-page: 171 year: 2000 ident: BFnpp2014166_CR101 publication-title: Pharmacol Ther doi: 10.1016/S0163-7258(00)00038-3 – volume: 8 start-page: 2575 year: 1997 ident: BFnpp2014166_CR64 publication-title: Neuroreport doi: 10.1097/00001756-199707280-00031 – volume: 14 start-page: 321 year: 2009 ident: BFnpp2014166_CR92 publication-title: Front Biosci (Landmark Ed) doi: 10.2741/3246 – volume: 25 start-page: 465 year: 2001 ident: BFnpp2014166_CR40 publication-title: Neurosci Biobehav Rev doi: 10.1016/S0149-7634(01)00027-6 – volume: 65 start-page: 278 year: 2011 ident: BFnpp2014166_CR38 publication-title: Synapse doi: 10.1002/syn.20844 – volume: 30 start-page: 7037 year: 2010 ident: BFnpp2014166_CR48 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0404-10.2010 – volume: 88 start-page: 8996 year: 1991 ident: BFnpp2014166_CR67 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.88.20.8996 – volume: 70 start-page: 28 year: 2011 ident: BFnpp2014166_CR55 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2010.09.021 – volume: 102 start-page: 1241 year: 2009 ident: BFnpp2014166_CR91 publication-title: J Neurophysiol doi: 10.1152/jn.91044.2008 – volume: 100 start-page: 797 year: 2000 ident: BFnpp2014166_CR47 publication-title: Neuroscience doi: 10.1016/S0306-4522(00)00286-4 – volume: 75 start-page: 789 year: 2003 ident: BFnpp2014166_CR80 publication-title: Pharmacol Biochem Behav doi: 10.1016/S0091-3057(03)00140-0 – volume: 109 start-page: E2657 year: 2012 ident: BFnpp2014166_CR59 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1206820109 – volume: 6 start-page: 635 year: 1999 ident: BFnpp2014166_CR69 publication-title: Curr Med Chem doi: 10.2174/0929867306666220401124036 – volume: 25 start-page: 6845 year: 2005 ident: BFnpp2014166_CR6 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0442-05.2005 – ident: BFnpp2014166_CR5 – volume: 34 start-page: 2368 year: 2009 ident: BFnpp2014166_CR21 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2009.71 – volume: 2008 start-page: 808564 year: 2008 ident: BFnpp2014166_CR62 publication-title: Neural Plast doi: 10.1155/2008/808564 – volume: 9 start-page: 475 year: 2003 ident: BFnpp2014166_CR46 publication-title: Neuroscientist doi: 10.1177/1073858403259137 – volume: 56 start-page: 1001 year: 1999 ident: BFnpp2014166_CR53 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.56.11.1001 – reference: 7746482 - Neurosci Lett. 1995 Jan 2;183(1-2):39-42 – reference: 6941317 - Proc Natl Acad Sci U S A. 1981 Apr;78(4):2643-7 – reference: 16648451 - Cereb Cortex. 2007 Mar;17(3):732-41 – reference: 18185500 - Neuropsychopharmacology. 2008 Sep;33(10):2505-16 – reference: 21130171 - Neuroimage. 2011 Mar 15;55(2):808-17 – reference: 20664082 - Physiol Rev. 2010 Jul;90(3):1195-268 – reference: 9460749 - Neuroscience. 1998 Mar;83(2):393-411 – reference: 24373053 - Addict Biol. 2015 Mar;20(2):357-67 – reference: 10998107 - Eur J Neurosci. 2000 Sep;12(9):3239-49 – reference: 6256518 - J Pharmacol Exp Ther. 1980 Oct;215(1):35-44 – reference: 10799713 - Pharmacol Ther. 2000 May;86(2):171-90 – reference: 19273069 - Front Biosci (Landmark Ed). 2009;14:321-32 – reference: 19716186 - Trends Neurosci. 2009 Sep;32(9):463-75 – reference: 8650228 - Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6112-7 – reference: 6187540 - Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):468-84 – reference: 19515947 - J Neurophysiol. 2009 Aug;102(2):1241-53 – reference: 21176026 - Bipolar Disord. 2010 Dec;12(8):793-803 – reference: 22443509 - Annu Rev Neurosci. 2012;35:203-25 – reference: 20345910 - Eur J Neurosci. 2010 Apr;31(7):1196-207 – reference: 9472392 - Neuroscience. 1997 Mar;77(2):299-318 – reference: 16033894 - J Neurosci. 2005 Jul 20;25(29):6845-56 – reference: 9208854 - Neuron. 1997 Jun;18(6):865-72 – reference: 17267760 - J Neurophysiol. 2007 Apr;97(4):2580-9 – reference: 10677026 - Neuron. 1999 Sep;24(1):49-65, 111-25 – reference: 11102663 - Int J Psychophysiol. 2000 Dec 1;38(3):211-23 – reference: 10565499 - Arch Gen Psychiatry. 1999 Nov;56(11):1001-5 – reference: 17662880 - Lancet. 2007 Jul 28;370(9584):319-28 – reference: 12428144 - Exp Brain Res. 2002 Dec;147(3):360-73 – reference: 10436069 - J Neurosci. 1999 Aug 15;19(16):7162-74 – reference: 9261830 - Neuroreport. 1997 Jul 28;8(11):2575-9 – reference: 5538858 - J Am Chem Soc. 1971 Jan 13;93(1):217-24 – reference: 22713908 - Neuropsychopharmacology. 2012 Sep;37(10):2184-93 – reference: 11595268 - Neurosci Biobehav Rev. 2001 Aug;25(6):465-76 – reference: 21702397 - Mil Med. 2011 Jun;176(6):718-20 – reference: 16022593 - Annu Rev Neurosci. 2005;28:157-89 – reference: 15372034 - Nature. 2004 Sep 16;431(7006):312-6 – reference: 12106295 - Eur J Neurosci. 1990;2(7):607-619 – reference: 18261715 - Biol Psychiatry. 2008 Jun 1;63(11):1075-83 – reference: 18466741 - Neuron. 2008 May 8;58(3):303-5 – reference: 18586694 - Schizophr Bull. 2008 Sep;34(5):944-61 – reference: 1880548 - J Neurosci. 1991 Sep;11(9):2768-85 – reference: 15812321 - Neuroreport. 2005 Apr 25;16(6):625-30 – reference: 2308954 - Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6 – reference: 22684592 - Am J Psychiatry. 2012 Jun;169(6):564-8 – reference: 2848184 - Mol Pharmacol. 1988 Nov;34(5):605-13 – reference: 16452670 - J Neurosci. 2006 Feb 1;26(5):1465-9 – reference: 18684772 - Schizophr Bull. 2008 Sep;34(5):907-26 – reference: 11036213 - Neuroscience. 2000;100(4):797-804 – reference: 20687106 - Synapse. 2011 Apr;65(4):278-86 – reference: 19571796 - Neuropsychopharmacology. 2009 Oct;34(11):2368-75 – reference: 16467563 - Cereb Cortex. 2007 Jan;17(1):175-91 – reference: 11879109 - JAMA. 2002 Mar 6;287(9):1123-31 – reference: 22927402 - Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64 – reference: 15102499 - J Neurosci Methods. 2004 Mar 15;134(1):9-21 – reference: 16364685 - Clin Neurophysiol. 2006 Jan;117(1):144-56 – reference: 11201089 - Neuroreport. 2001 Jan 22;12(1):43-7 – reference: 20542094 - Neuroscience. 2010 Sep 15;169(4):1651-61 – reference: 20484646 - J Neurosci. 2010 May 19;30(20):7037-48 – reference: 17360907 - J Neurosci. 2007 Mar 14;27(11):2858-65 – reference: 14678580 - Neuroscientist. 2003 Dec;9(6):475-84 – reference: 12202074 - Neuroimage. 2002 Aug;16(4):843-56 – reference: 23899642 - J Clin Psychopharmacol. 2013 Oct;33(5):699-705 – reference: 18400208 - Biol Psychiatry. 2008 Sep 1;64(5):369-75 – reference: 18394789 - Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S84-90 – reference: 18674887 - Eur Neuropsychopharmacol. 2008 Nov;18(11):826-34 – reference: 9336020 - Pharmacol Ther. 1997;74(2):129-80 – reference: 18466752 - Neuron. 2008 May 8;58(3):429-41 – reference: 14977366 - Crit Rev Neurobiol. 2003;15(2):91-119 – reference: 19634950 - Behav Neurosci. 2009 Aug;123(4):894-904 – reference: 681612 - J Abnorm Psychol. 1978 Aug;87(4):399-407 – reference: 9203002 - Int J Psychophysiol. 1997 Jun;26(1-3):171-89 – reference: 20087360 - Nat Rev Neurosci. 2010 Feb;11(2):100-13 – reference: 21300939 - Arch Gen Psychiatry. 2011 Jun;68(6):555-61 – reference: 17637608 - Neuropsychopharmacology. 2008 May;33(6):1432-40 – reference: 17115043 - Nat Neurosci. 2006 Dec;9(12):1526-33 – reference: 20813412 - Psychiatry Res. 2011 Mar 30;186(1):46-52 – reference: 21111401 - Biol Psychiatry. 2011 Jul 1;70(1):28-34 – reference: 20487147 - J Forensic Sci. 2010 Sep;55(5):1209-17 – reference: 15218136 - Science. 2004 Jun 25;304(5679):1926-9 – reference: 12790346 - Int J Audiol. 2003 Jun;42(4):177-219 – reference: 12957220 - Pharmacol Biochem Behav. 2003 Jul;75(4):789-93 – reference: 10469884 - Curr Med Chem. 1999 Aug;6(8):635-64 – reference: 1924362 - Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8996-9000 – reference: 19668703 - Front Integr Neurosci. 2009 Jul 30;3:17 – reference: 21079038 - Pharmacol Rev. 2010 Dec;62(4):588-631 – reference: 20566335 - Toxicol Lett. 2010 Sep 1;197(3):157-62 – reference: 23269835 - Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):719-24 – reference: 7854418 - Nature. 1995 Feb 16;373(6515):612-5 – reference: 17222464 - Trends Pharmacol Sci. 2007 Feb;28(2):83-92 – reference: 8857537 - Nature. 1996 Oct 17;383(6601):621-4 – reference: 12960382 - Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11047-52 – reference: 21747398 - Mol Psychiatry. 2012 Jun;17(6):642-9 – reference: 18801434 - Curr Opin Neurobiol. 2008 Jun;18(3):338-45 – reference: 10842224 - J Comp Neurol. 2000 Jun 26;422(2):159-71 – reference: 23822952 - Neuropsychopharmacology. 2013 Nov;38(12):2338-47 – reference: 19079598 - Neural Plast. 2008;2008:808564 – reference: 17012692 - Am J Psychiatry. 2006 Oct;163(10):1798-805 |
| SSID | ssj0015768 |
| Score | 2.251342 |
| Snippet | Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80 Hz). However, no studies to... Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30-80Hz). However, no studies to date... Previous work in animals and humans has shown that exogenous cannabinoids disrupt time-locked, evoked gamma oscillations (30–80 Hz). However, no studies to... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 3087 |
| SubjectTerms | Adolescent Adult Analysis of Variance Biological and medical sciences Brain Mapping Cannabinoids Electroencephalography Female Fourier Analysis Gamma Rhythm - physiology Humans Linear Models Male Marijuana Marijuana Abuse - complications Medical sciences Motion Perception - physiology Neural networks Original Perceptual Disorders - etiology Photic Stimulation Surveys and Questionnaires Tetrahydrocannabinol THC Young Adult |
| Title | Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24990428 https://www.proquest.com/docview/1622075904 https://www.proquest.com/docview/1622597266 https://www.proquest.com/docview/1664205470 https://pubmed.ncbi.nlm.nih.gov/PMC4229582 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9swED-2FsZgjC3dw10XNNj6ZXVryS_l0-hzYZAujAbyzZwsmwUaJa2TQf776WTHWca6zz4jodNJv3vodwAfibFFKxX7MlfCJ_5ya1IR-iiiUGDAUTie7sF10h9F38bxuAm4VU1Z5fpMdAe1nuUUIz_hiRD2eusF0Zf5nU9doyi72rTQeAy7RF1GJV3puHW4OGFphyJ7oW99sXFT-B6E8sTMiaySR8fc8SNurqRnc6zs6pR1W4t_4c6_yyf_uI-uXsDzBkiy01rzL-FRYTqwd2qsEz1dsUPmSjtdzLwDTwZNBr0Dh8Oaq3p1xG42T6-qI_dHy2K92gN1Manul3MLSNlXnE7RP0OjGXF52FG_24vztqmiYxfupSOjhx5E9cQGrjEQG7YlM2xiWL_AXyt2jsagmlRsRI88X8Ho6vLmvO83DRn83AKfha-wF2AS5CLpFUkYClXEWskSk7IoRVCkPEoLTMNQJRGXGKWl1JyMXAZxnHOlw9ewY2ameAssR65VjlITH10sAwy55hojnkpivSs9-LzWSZY3bOXUNOM2c1nzUGZWgxlpMLMa9OBTKz2vWToekOtuqbcVJrfTYpnUg4O1vrPGmKtss_U8-NB-tmZIuRU0xWxZy1jfTNAYD8tYZ89C5DTw4E29hTYTsJ4nua8epFubqxUgGvDtL2by09GBR9SRXYr9_0_9HTylVagrcQ5gZ3G_LN5bPLVQXWc0Xdg9u7we_ui6gNdvoG0ixg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIkhCDlYShlkWgv1NT7sL05INQ2LSltQlQlUm5m1w8RqXFMnYDyp_iN7NiOQxDl1rPHXsszuzOfZ-YbgLfI2BJp7doy1MxG_nKzpYSyFROcKYcqVvB0d3teZyg-j9zRBvxa9sJgWeXyTCwO6mga4j_yA-oxZtxbyxEfs-82To3C7OpyhEZpFufx4qeBbPmHs7bR7y5jpyeD445dTRWwQ-O9Z7ZWLUd5Tsi8VuxxznTsRlomykvihDmxT4UfK59z7QkqlfATGVG0VOm4bkh1xM1z78Cm4AbKNGDz6KTXv6zzFhi9F3Fri9sG_Y2qUnuHy4M0Q3pMKt7TgpFx5QQfZCo3-kjKQRr_inT_Ltj8wwOePoKHVehKDktbewwbcdqErcPUwPbJguyRopi0-EvfhLvdKmffhL1-yY692CeDVbNXvl_cUfNmL7ZAt8f59TwzITD5pCYTZR-pNCLIHmJW_WJc9VVVt0faRW8lwdYSJJci3WIUEenXRTpknJJOrH4syLFKU6XHORliW-kTGN6Ksp5CI52m8XMgoaKRDpWMkAHPlY7iNKKREtSXyLOXWPBuqZMgrPjRcUzHVVDk6bkMjAYD1GBgNGjBbi2dlbwgN8jtrKm3Fkaga6In34Ltpb6D6vjIg5WxW_Cmvmw2PmZzVBpP56WMQYMM17hZxsBLE5T7jgXPShNavYDBugiYLfDXjKsWQOLx9Svp-FtBQC5wBrxkL_7_6q_hXmfQvQguznrnL-E-fpGyDmgbGrPrefzKRHMzvVNtIQJfb3vX_gYxeF4H |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIU1ICEHHR2AMI7G9sNDYzof7gNBYKR2jow-r1LdgJ46otKZhaUH91_jr8DlpShHjbc-5xFF-d767-O53AK-QsSVVKnBFopiL_OXGpHzpSuZzJj0qmeXpHpyH_ZH_aRyMt-DXqhcGyypXe6LdqNNZgv_I2zRkzLi3jue3s7osYtjtvSu-uzhBCk9aV-M0KhU508ufJn0r3552DdYHjPU-XJz03XrCgJsYTz53lex4MvQSFnZ0yDlTOkiVyGSY6Yx5OqJ-pGXEuQp9KqQfZSKlqLXCC4KEqpSb596C2xEPKNpYNG6SPYpxvI1gO9w1eeC4Lrr3uGjnBRJlUv8NtdyMa3d4t5ClQSarRmr8K-b9u3TzD1_Yuw_36iCWHFda9wC2dN6C3ePcJPDTJTkktqzU_q9vwc6gPr1vweGw4sleHpGLddtXeWTvaBi0l7ugupPyalGYYJh8lNOpdN_LPCXII2JW_WKc9mVdwUe6tsuSYJMJ0kyRgR1KRIZNuQ6Z5KSv5Y8lOZF5LtWkJCNsMH0IoxuB6hFs57NcPwGSSJqqRIoUufAC4UlOU5pKn0YCGfcyB16vMImTmikdB3ZcxvbEnovYIBgjgrFB0IGDRrqoGEKukdvfgLcRxpTXxFGRA3srvON6Iynjtdo78LK5bLYAPNeRuZ4tKhmTFzJc43oZk2ia8DzyHHhcqdD6BUzWi6mzA9GGcjUCSEG-eSWffLNU5D5Ogxfs6f9f_QXsGFuNP5-enz2DO_hBqoKgPdieXy30cxPWzdW-tR8CX2_aYH8DfKVg1w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Disrupted+Gamma-Band+Neural+Oscillations+During+Coherent+Motion+Perception+in+Heavy+Cannabis+Users&rft.jtitle=Neuropsychopharmacology+%28New+York%2C+N.Y.%29&rft.au=Skosnik%2C+Patrick+D&rft.au=Krishnan%2C+Giri+P&rft.au=D%27Souza%2C+Deepak+C&rft.au=Hetrick%2C+William+P&rft.date=2014-12-01&rft.issn=0893-133X&rft.volume=39&rft.issue=13&rft.spage=3087&rft.epage=3099&rft_id=info:doi/10.1038%2Fnpp.2014.166&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-133X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-133X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-133X&client=summon |